EA201790179A1 - [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний - Google Patents

[1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний

Info

Publication number
EA201790179A1
EA201790179A1 EA201790179A EA201790179A EA201790179A1 EA 201790179 A1 EA201790179 A1 EA 201790179A1 EA 201790179 A EA201790179 A EA 201790179A EA 201790179 A EA201790179 A EA 201790179A EA 201790179 A1 EA201790179 A1 EA 201790179A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridazines
triazolo
treatment
proliferative diseases
agents
Prior art date
Application number
EA201790179A
Other languages
English (en)
Other versions
EA032654B1 (ru
EA032654B9 (ru
Inventor
Роберт Хью Брэдбери
Алфред Артур Рабоу
Майкл Джеймс Уэринг
Джеймс Фрэнсис МакКабе
Стивен Кристофер Глоссоп
Аршед Махмуд
Зои Энн Коттер
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201790179A1 publication Critical patent/EA201790179A1/ru
Publication of EA032654B1 publication Critical patent/EA032654B1/ru
Publication of EA032654B9 publication Critical patent/EA032654B9/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • EFIXED CONSTRUCTIONS
    • E21EARTH OR ROCK DRILLING; MINING
    • E21BEARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00Special methods or apparatus for drilling
    • E21B7/04Directional drilling
    • E21B7/06Deflecting the direction of boreholes
    • EFIXED CONSTRUCTIONS
    • E21EARTH OR ROCK DRILLING; MINING
    • E21BEARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00Special methods or apparatus for drilling
    • E21B7/04Directional drilling
    • E21B7/06Deflecting the direction of boreholes
    • E21B7/062Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Geology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Environmental & Geological Engineering (AREA)
  • Physics & Mathematics (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Fluid Mechanics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I)или их фармацевтически приемлемым солям, где R, Rи n имеют какое-либо из значений, определенных в описании изобретения; способам их получения, фармацевтическим композициям, содержащим их, и их применению в качестве антипролиферативных средств и/или средств, обеспечивающих гибель клеток.
EA201790179A 2014-07-28 2015-07-24 [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ EA032654B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
EA201790179A1 true EA201790179A1 (ru) 2017-07-31
EA032654B1 EA032654B1 (ru) 2019-06-28
EA032654B9 EA032654B9 (ru) 2019-07-31

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790179A EA032654B9 (ru) 2014-07-28 2015-07-24 [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ

Country Status (36)

Country Link
US (5) US9944650B2 (ru)
EP (1) EP3174881B1 (ru)
JP (1) JP6592503B2 (ru)
KR (1) KR20170033427A (ru)
CN (1) CN106536524B (ru)
AP (1) AP2017009700A0 (ru)
AU (1) AU2015295120B2 (ru)
BR (1) BR112017001160A2 (ru)
CA (2) CA2956421C (ru)
CL (1) CL2017000223A1 (ru)
CO (1) CO2017001918A2 (ru)
CY (1) CY1120602T1 (ru)
DK (1) DK3174881T3 (ru)
DO (1) DOP2017000018A (ru)
EA (1) EA032654B9 (ru)
ES (1) ES2670444T3 (ru)
GT (1) GT201700016A (ru)
HR (1) HRP20180788T1 (ru)
HU (1) HUE037571T2 (ru)
IL (1) IL250104B (ru)
LT (1) LT3174881T (ru)
MX (1) MX2017001218A (ru)
MY (1) MY187251A (ru)
NI (1) NI201700006A (ru)
NO (2) NO2719005T3 (ru)
PE (1) PE20170527A1 (ru)
PH (1) PH12017500159A1 (ru)
PL (1) PL3174881T3 (ru)
PT (1) PT3174881T (ru)
RS (1) RS57242B1 (ru)
SG (1) SG11201700419SA (ru)
SI (1) SI3174881T1 (ru)
SV (1) SV2017005368A (ru)
TN (1) TN2017000018A1 (ru)
WO (1) WO2016016618A1 (ru)
ZA (1) ZA201701207B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (ru) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥(上海)股份有限公司 治療前列腺癌之組合療法
AU2020367035A1 (en) 2019-10-14 2022-05-12 Astrazeneca Ab Combination therapy for treating a hematological malignancy
CA3166741A1 (en) 2020-01-09 2021-07-15 Astrazeneca Ab Combination therapy for treating cancer
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP1963316A2 (en) 2005-12-08 2008-09-03 Novartis AG Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
WO2009081197A1 (en) 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
AU2010212590B2 (en) * 2009-02-10 2013-01-10 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
CN102482280A (zh) * 2009-05-11 2012-05-30 阿斯利康(瑞典)有限公司 作为雄激素受体的配体的[1,2,4]三唑并[4,3-b]哒嗪
SI2496580T1 (sl) 2009-11-05 2014-02-28 Glaxosmithkline Llc Benzodiazepinski inhibitorji bromodomene
US9328117B2 (en) * 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (ru) * 2014-07-28 2018-01-20

Also Published As

Publication number Publication date
AU2015295120A1 (en) 2017-02-02
NO2719005T3 (ru) 2018-01-20
EP3174881A1 (en) 2017-06-07
PH12017500159B1 (en) 2017-07-10
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
US20170210747A1 (en) 2017-07-27
EP3174881B1 (en) 2018-03-28
NO3174881T3 (ru) 2018-08-25
PT3174881T (pt) 2018-05-25
PL3174881T3 (pl) 2018-08-31
US20200055861A1 (en) 2020-02-20
CN106536524B (zh) 2019-11-15
DK3174881T3 (en) 2018-06-06
DOP2017000018A (es) 2017-03-15
ZA201701207B (en) 2018-12-19
LT3174881T (lt) 2018-06-11
CA3185741A1 (en) 2016-02-04
ES2670444T3 (es) 2018-05-30
JP2017522338A (ja) 2017-08-10
WO2016016618A1 (en) 2016-02-04
AP2017009700A0 (en) 2017-01-31
JP6592503B2 (ja) 2019-10-16
PH12017500159A1 (en) 2017-07-10
US20210107905A1 (en) 2021-04-15
EA032654B1 (ru) 2019-06-28
CY1120602T1 (el) 2019-12-11
TN2017000018A1 (en) 2018-07-04
SV2017005368A (es) 2017-05-12
CO2017001918A2 (es) 2017-05-10
BR112017001160A2 (pt) 2017-11-14
MY187251A (en) 2021-09-15
GT201700016A (es) 2018-12-19
US11407755B2 (en) 2022-08-09
HRP20180788T1 (hr) 2018-06-29
SI3174881T1 (en) 2018-06-29
AU2015295120B2 (en) 2018-02-01
IL250104A0 (en) 2017-03-30
AU2015295120A8 (en) 2017-02-09
CA2956421A1 (en) 2016-02-04
US9944650B2 (en) 2018-04-17
NI201700006A (es) 2017-08-25
US10407432B2 (en) 2019-09-10
RS57242B1 (sr) 2018-07-31
US20230035133A1 (en) 2023-02-02
EA032654B9 (ru) 2019-07-31
IL250104B (en) 2018-10-31
SG11201700419SA (en) 2017-02-27
CA2956421C (en) 2023-03-14
US20180230158A1 (en) 2018-08-16
US10766905B2 (en) 2020-09-08
CN106536524A (zh) 2017-03-22
CL2017000223A1 (es) 2017-08-25
HUE037571T2 (hu) 2018-09-28
KR20170033427A (ko) 2017-03-24

Similar Documents

Publication Publication Date Title
CY1120734T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12015502615B1 (en) Chemical compounds
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
MD20170070A2 (ru) Производные хиназолина, используемые при лечении ВИЧ
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EA201690752A1 (ru) Ингибиторы g12c kras
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
TW201613864A (en) Novel compounds
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent